CHANG NANCY T 4

4 · Galera Therapeutics, Inc. · Filed Apr 9, 2026

AI-generated summary of this filing

Updated Apr 9, 2026

Galera Therapeutics (GRTX) 10% Owner Nancy Chang Receives 1.18M Shares

What Happened

Nancy T. Chang, a reported 10% owner of Galera Therapeutics (GRTX), had Series B non‑voting convertible preferred shares converted into common stock on April 7, 2026. The filing shows 1,180.611 shares of Series B preferred were converted into 1,180,611 shares of common stock. No cash was paid or received in the conversion (price reported as $0.00 / N/A).

Key Details

Transaction date: April 7, 2026; Form 4 filed April 9, 2026 (appears timely, within the two‑business‑day window).
Conversion: 1,180.611 shares of Series B preferred → 1,180,611 common shares.
Reported price/value: $0.00 or N/A (corporate conversion, not a purchase/sale).
Shares owned after the transaction: Not specified in the filing.
Footnote: On Feb 12, 2026 the company amended the Series B designation to allow the board to elect a mandatory conversion at its sole discretion; the April 7 conversion was a partial mandatory conversion and the Series B shares have no expiration (see F1).

Context

This was a corporate mandatory conversion of preferred into common stock, not an open‑market buy or sale by the insider—so it does not directly signal a buy or sell decision by Chang.
The conversion ratio used by the company is 1,000 common shares per 1 share of Series B preferred (which explains the 1,180.611 preferred → 1,180,611 common conversion).

Form 4

Period: 2026-04-07

Director10% Owner

Transactions

Conversion
Common Stock
[F1]
2026-04-07+1,180,611→ 8,825,543 total
Conversion
Series B Preferred Stock
[F1]
2026-04-07−1,180.611→ 661.309 total
→ Common Stock (1,180,611 underlying)

Footnotes (1)

[F1]On February 12, 2026, the Issuer filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Common Stock calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On April 7, 2026, the Issuer effected a partial Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock have no expiration date.

Signature

/s/ J. Mel Sorensen, Attorney-in-Fact for Nancy T. Chang|2026-04-09

1 file